Study of Phenobarbital Inhibition of Catamenial Epilepsy

Withdrawn before enrolling · Not applicable · Has a placebo group

Conditions studied: Epilepsy

In brief

The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy. We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.

Key facts

Study ID
NCT00530413
Run by
University of Toledo Health Science Campus
People needed
0
Starts
2007-03-01
Last updated by the study team
2014-12-10

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.